Creation of a New 70 Million Euro Vetter Production Building
News Mar 23, 2016
Vetter has announced the construction of a new building at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site. Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million), it is part of the total investment strategy announced by the company in September 2015, and will constitute an important element in the overall Schuetzenstrasse facility rebuilding concept for modernization and expansion.
Upon completion, the seven story building will cover a total of 8,000 sq. meters (86,000 sq. ft), and include in its core a cleanroom with supportive media systems. Additionally, it will contain the site’s central material preparation; office space for the production staff as well as a staff canteen with roof garden. The applied technology of the cleanroom will be dedicated to the filling of bulk syringes and designed to be compatible for the filling of sensitive drugs such as biologics and opthalmics.
Syringes prepared in the bulk process offer a number of customization options that are tailored to substance and primary packaging material components, and offer customizable low silicone levels and thus, process flexibility. Another central technological element of the cleanroom will be the implementation of an improved restricted access barrier system (RABS) concept to combine the advantages of isolator and RABS technology.
The core of this innovative approach is a uniquely fast, by today’s standards, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H2O2).“This addition to our Schuetzenstrasse site is an exciting chapter in our company’s history and will again support Vetter’s target to offer its customers the adequate high manufacturing quality for their high value drugs”, said Vetter Managing Director Thomas Otto.“Attaining this high level of quality is of particular significance to Vetter as it represents one of our core customer relations value propositions.”
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018